Compare · SBBP vs XERS
SBBP vs XERS
Side-by-side comparison of Strongbridge Biopharma plc (SBBP) and Xeris Biopharma Holdings Inc. (XERS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. SBBP focuses on Major Pharmaceuticals, while XERS focuses on Biotechnology: Pharmaceutical Preparations.
- XERS is the larger of the two at $1.16B, about 8.5x SBBP ($136.0M).
- XERS has hit the wire 12 times in the past 4 weeks while SBBP has been quiet.
- XERS has more recent analyst coverage (12 ratings vs 0 for SBBP).
- Company
- Strongbridge Biopharma plc
- Xeris Biopharma Holdings Inc.
- Price
- $2.00+1.78%
- $6.71+3.39%
- Market cap
- $136.0M
- $1.16B
- 1M return
- -
- +9.64%
- 1Y return
- -
- +53.55%
- Industry
- Major Pharmaceuticals
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2018
- News (4w)
- 0
- 12
- Recent ratings
- 0
- 12
Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Xeris Biopharma Holdings Inc.
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Latest SBBP
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 15-12B filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Cohen Fredric J. returned 160,408 units of Ordinary Shares to the company, decreasing direct ownership by 50% to 160,408 units
Latest XERS
- Director Kong Garheng was granted 24,193 shares, increasing direct ownership by 11% to 238,337 units (SEC Form 4)
- Director Persky Marla sold $91,433 worth of shares (15,500 units at $5.90) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)
- Director Halkuff Dawn sold $121,886 worth of shares (20,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 4% to 119,193 units (SEC Form 4)
- Director Bormann-Kennedy Barbara-Jean Anne sold $97,507 worth of shares (16,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 6% to 150,693 units (SEC Form 4)
- Director Johnson John sold $91,422 worth of shares (15,000 units at $6.09) as part of a pre-agreed trading plan and was granted 24,193 shares, increasing direct ownership by 1% to 707,276 units (SEC Form 4)
- Director Brady James Aloysius was granted 24,193 shares, increasing direct ownership by 27% to 113,359 units (SEC Form 4)
- Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 144 filed by Xeris Biopharma Holdings Inc.
- SEC Form 144 filed by Xeris Biopharma Holdings Inc.
- SEC Form 144 filed by Xeris Biopharma Holdings Inc.